Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Diagn Microbiol Infect Dis ; 92(2): 164-167, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29884563

RESUMO

The aim of the present study was to propose epidemiologic cutoffs that could be used in routine practice to separate wild-type from non-wild-type Campylobacter fetus to ciprofloxacin. A total of 123 C. fetus isolates obtained from human samples were used for this purpose. Based on the determination of inhibition zone diameter, minimum inhibitory concentration, and sequencing of the quinolone resistance determining region in the gyraseA gene, for all tested isolates, the following cutoffs were proposed: ciprofloxacin-wild type if the inhibition zone diameter was ≥22 mm or the minimum inhibitory concentration was ≤0.5 mg/L.


Assuntos
Antibacterianos/farmacologia , Infecções por Campylobacter/epidemiologia , Campylobacter fetus/efeitos dos fármacos , Ciprofloxacina/farmacologia , Fluoroquinolonas/farmacologia , Infecções por Campylobacter/microbiologia , Campylobacter fetus/genética , Campylobacter fetus/isolamento & purificação , Humanos , Testes de Sensibilidade Microbiana
2.
Ann Oncol ; 23(5): 1320-1324, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21917738

RESUMO

BACKGROUND: In epidemiological studies, Helicobacter pylori infection is usually detected by enzyme-linked immunosorbent assay (ELISA). However, infection can spontaneously clear from the mucosa during the progression of atrophy and could lead to substantial under-detection of infection and underestimation of its effect on gastric cancer (GC) risk. Antibodies detected by western blot are known to persist longer after the loss of the infection. METHODS: In a nested case-control study from the Eurogast-EPIC cohort, including 88 noncardia GC cases and 338 controls, we assessed the association between noncardia GC and H. pylori infection comparing antibodies detected by western blot (HELICOBLOT2.1) to those detected by ELISA (Pyloriset EIA-GIII(®)). RESULTS: By immunoblot, 82 cases (93.2%) were H. pylori positive, 10 of these cases (11.4%) were negative by ELISA and only 6 cases (6.8%) were negative by both ELISA and immunoblot. Multivariable odds ratio (OR) for noncardia GC comparing immunoglobulin G positive versus negative by ELISA was 6.8 [95% confidence interval (CI) 3.0-15.1], and by immunoblot, the OR was 21.4 (95% CI 7.1-64.4). CONCLUSIONS: Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC.


Assuntos
Adenocarcinoma/etiologia , Infecções por Helicobacter/diagnóstico , Helicobacter pylori/imunologia , Immunoblotting/métodos , Neoplasias Gástricas/etiologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/epidemiologia , Adulto , Idoso , Anticorpos Antibacterianos/análise , Anticorpos Antibacterianos/sangue , Cárdia/patologia , Estudos de Casos e Controles , Estudos de Coortes , Ensaio de Imunoadsorção Enzimática/métodos , Europa (Continente)/epidemiologia , Infecções por Helicobacter/complicações , Infecções por Helicobacter/epidemiologia , Infecções por Helicobacter/imunologia , Helicobacter pylori/isolamento & purificação , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Estudos Soroepidemiológicos , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...